Net sales and operating results improved year-over-year, with key portfolio companies achieving clinical and commercial milestones. Despite a sharp decline in listed portfolio value, the company maintains a strong equity ratio and continues to pursue strategic investments in medtech and life science.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.